For upside au prix d'une forte dilution - ACHAT - OC 9,7€ (vs 11,5€)
La société a publié, fin juin, les résultats complets de QGC001 en phase IIa, dans le traitement de l’HyperTension Artérielle. Malgré des résultats qui confirment tout l’intérêt du composé de cibler les patients présentant une HTA sévère, le marché a durement pénalisé la société. Au vu de ces résultats, nous ajustons notre cible potentielle en HTA et intégrons dorénavant l’IC dont les résultats sont attendus lors du S1 18 (phase IIa). De plus dans le but de sécuriser le lancement de la phase II aux US en HTA, QG a annoncé un placement privé d’un montant de 8,2m€ hier soir. Ces différents éléments nous conduisent à ajuster notre OC qui passe de 11,5€ à 9,7€. ACHAT maintenu.Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.